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Summary
Background.  —  Regionalization  of  care  for  ST-segment  elevation  myocardial  infarction  (STEMI)
has been  advocated,  although  its  effect  on  processes  of  care  and  clinical  outcomes  remains
uncertain.
Abbreviations: FAST-MI, French registry of Acute ST-elevation and non-ST-elevation Myocardial Infarction; IQR, interquartile range; PCI,
ercutaneous coronary intervention; RESURCOR, RESeau d’URgences CORonariennes; STEMI, ST-segment elevation myocardial infarction.
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Aim.  —  To  assess  the  impact  of  a  regional  system  of  care  on  provision  of  reperfusion  therapy  for
STEMI patients  relative  to  control  hospitals.
Methods.  —  We  analysed  the  original  data  from  two  nationwide  prospective  cohort  studies  con-
ducted in  2000  and  2005,  respectively.  Overall,  160  hospitals  participated  in  both  studies,
including seven  hospitals  involved  in  a  regional  system  of  care  implemented  in  the  Northern
Alps in  2002  and  153  control  hospitals  located  in  other  French  areas.
Results.  —  A  total  of  102  and  2377  STEMI  patients  were  enrolled  in  Northern  Alps  and  con-
trol hospitals,  respectively.  Overall,  patients  enrolled  in  2005  were  more  likely  to  receive  any
reperfusion  therapy  (60%  vs  52%;  P  <  0.001),  prehospital  ﬁbrinolysis  (33%  vs  15%;  P  <  0.001),  and
primary percutaneous  coronary  intervention  (32%  vs  26%;  P  <  0.001)  than  those  enrolled  in  2000.
However,  the  regional  system  of  care  was  associated  with  a  larger  absolute  change  in  the  use  of
prehospital  ﬁbrinolysis  (45.0  vs  17.0;  P  =  0.02)  and  rescue  or  early  routine  coronary  angiography
or intervention  after  ﬁbrinolysis  (35.3  vs  15.2;  P  =  0.01).  Patients  enrolled  in  2005  had  lower
adjusted hazard  ratios  for  death  (0.70,  95%  conﬁdence  interval  0.57—0.87;  P  =  0.001),  with  no
signiﬁcant  interaction  between  study  groups.
Conclusion.  —  Regionalization  of  care  for  STEMI  patients  improves  access  to  reperfusion  therapy,
although  its  impact  on  clinical  outcomes  deserves  further  study.
© 2012  Elsevier  Masson  SAS.  All  rights  reserved.
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Résumé
Contexte.  — Les  recommandations  préconisent  une  coordination  régionale  de  la  prise  en  charge
de l’infarctus  du  myocarde  avec  sus-décalage  du  segment  ST  (STEMI).
Objectif.  — Évaluer  l’impact  d’un  réseau  de  soins  dédié  à  la  prise  en  charge  des  patients  avec
un STEMI.
Méthodes.  — Nous  avons  analysé  les  données  originales  provenant  de  deux  études  de  cohorte
prospectives  multicentriques  conduites  en  France  en  2000  et  2005.  Au  total,  160  hôpitaux  ont
participé aux  deux  études,  dont  sept  hôpitaux  impliqués  dans  un  réseau  de  soins  mis  en  place
en 2002  dans  les  Alpes  du  Nord  et  153  hôpitaux  témoins  situés  sur  le  reste  du  territoire  national.
Résultats.  — Cent  deux  patients  ont  été  inclus  dans  les  hôpitaux  des  Alpes  du  Nord  et  2377  dans
les hôpitaux  situés  sur  le  reste  du  territoire  national.  Globalement,  les  patients  recrutés  en
2005 avaient  plus  souvent  eu  accès  à  une  ﬁbrinolyse  préhospitalière  (33  %  versus  15  %  ;  p  <  0,001)
ou à  une  angioplastie  coronaire  percutanée  primaire  (32  %  versus  26  %  ;  p  <  0,001).  Cependant,
le réseau  de  soins  était  associé  à  une  augmentation  plus  importante  de  la  proportion  de  patients
avec une  ﬁbrinolyse  préhospitalière  (45  %  versus  17  %  ;  p  =  0,02)  et  une  angioplastie  coronaire
percutanée  secondaire  ou  de  sauvetage  (35  %  versus  15  %  ;  p  =  0,01).  Le  risque  de  décès  était
plus faible  en  2005  (0,70,  intervalle  de  conﬁance  à  95  %  0,57—0,87  ;  p  =  0,001),  sans  qu’on  puisse
mettre en  évidence  de  différence  en  fonction  du  groupe.
Conclusion.  —  La  mise  en  place  d’un  réseau  de  soins  a  amélioré  l’accès  aux  stratégies  de
revascularisation  des  patients  admis  avec  un  STEMI  dans  les  hôpitaux  des  Alpes  du  Nord.
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Background
Prompt  coronary  reperfusion  therapy  for  ST-segment  ele-
vation  myocardial  infarction  (STEMI)  limits  infarct  size  and
improves  survival  [1].  Current  guidelines  advocate  primary
percutaneous  coronary  intervention  (PCI)  as  the  preferred
method  for  reperfusion  in  STEMI  as  long  as  the  expected  time
from  the  ﬁrst  medical  contact  to  the  coronary  balloon  inﬂa-
tion  is  less  than  2  hours  [2,3]. Otherwise,  patients  should
receive  ﬁbrinolysis  therapy,  preferably  administered  prehos-
pital  [4],  and  then  be  directed  to  a  PCI-capable  centre  where
coronary  angiography  and  intervention  can  be  performed  in
a  time  window  of  3—24  hours  [5].Unfortunately,  STEMI  registries  consistently  report  delays
in  reperfusion  that  exceed  those  recommended  by  guide-
lines  and  substantial  proportions  of  patients  who  are  denied
any  reperfusion  therapy  [1,6—8]. Because  the  reasons  for
s
o
rs  droits  réservés.
hese  observations  are  partly  related  to  systemic  barri-
rs  [9,10], systems  of  care  have  been  developed  through
egional  networks  to  broaden  the  use  of  reperfusion  therapy
nd  to  facilitate  timely  access  to  primary  PCI  for  patients
resenting  to  hospitals  without  PCI  capability  [11,12].
Several  studies  have  reported  a  signiﬁcant  reduction  in
ime  to  reperfusion  therapy  and  increased  access  to  pri-
ary  PCI  following  the  implementation  of  regional  systems
f  care  for  STEMI  [13—18]. However,  these  studies  did  not
nclude  regional  or  national  comparators  [15,17,18], lacked
 historical  control  group  [13,14]  or  had  limited  gener-
lizability  because  of  their  location  in  large  urban  areas
16].Pooling  the  original  data  from  two  prospective  cohort
tudies,  we  examined  the  impact  of  a  regional  system  of  care
n  the  provision  of  reperfusion  therapy  for  STEMI  patients
elative  to  a  nationwide  sample  of  control  hospitals.
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demographics,  cardiovascular  history,  risk  factors,  comorbid16  
ethods
tudy design
e  retrospectively  designed  a  controlled  pre-  and  postin-
ervention  study  evaluating  a  regional  system  of  care  that
as  implemented  in  October  2002  in  the  Northern  Alps  in
rance.  Pre-  and  postintervention  data  were  extracted  from
he  USIC  2000  and  French  registry  of  Acute  ST-elevation
nd  non-ST-elevation  Myocardial  Infarction  (FAST-MI)  stud-
es,  which  were  conducted  in  2000  and  2005,  respectively.
o  adjust  for  secular  trends  and  sudden  changes  [19], hos-
itals  located  in  other  French  mainland  areas  served  as
ontrols.
The  rationale,  design  and  primary  outcomes  of  the  USIC
000  and  FAST-MI  studies  have  been  described  in  detail  else-
here  [20,21].  Brieﬂy,  the  two  studies  were  nationwide
rospective  observational  cohort  studies  designed  to  collect
omplete  and  representative  data  on  processes  of  care  and
linical  outcomes  for  patients  with  acute  myocardial  infarc-
ion  who  were  admitted  to  participating  hospitals  over  a
-month  period  in  France.
tudy sites
he  USIC  2000  and  FAST-MI  studies  involved  316  and  222  hos-
itals  with  intensive  care  units,  respectively.  Of  these,  160
ospitals  participated  in  both  studies,  including  seven  North-
rn  Alps  hospitals  involved  in  the  regional  system  of  care  and
53  control  hospitals  (Table  1).
c
a
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Table  1 Site  of  admission  characteristics  in  2005.
Characteristics  Northern  Alps  
Ownership
Public 6 (85.7)  
Private,  for-proﬁt 1 (14.3)  
Private,  not-for-proﬁt  —  (—)  
Veterans  Affairs  —  (—)  
Academic  hospitals  1  (14.3)  
Region
Paris  and  surrounding  area  —  (—)  
Northwest  —  (—)  
Northeast  —  (—)  
Southeast  7  (100)  
Southwest  —  (—)  
Licensed  beds
< 200  1  (14.3)  
200—599  4  (57.1)  
≥  600  2  (28.6)  
Cardiac  procedure  capabilitiesa
Cardiac  catheterization  4  (57.1)  
PCI  3  (42.9)  
CABG  2  (28.6)  
Data are n (%). CABG: coronary artery bypass graft; PCI: percutaneous
a In 2000, four Northern Alps and 92 control hospitals had cardiac cathe
had percutaneous coronary capabilities and two Northern Alps and 35 J.  Labarère  et  al.
atients
hysicians  at  participating  hospitals  enrolled  consecutive
atients  24  hours/day,  7  days/week,  over  a  1-month  period
i.e.  in  November  2000  for  the  USIC  2000  study  and  in  Octo-
er  2005  for  the  FAST-MI  study).  Adult  patients  were  eligible
f  they  had:  concentrations  of  serum  markers  of  myocar-
ial  necrosis  (creatine  kinase,  creatine  kinase-MB,  troponin
 or  troponin  T)  that  were  more  than  twice  the  upper  limit
f  the  normal  range;  and  either  symptoms  consistent  with
cute  myocardial  infarction  or  electrocardiographic  changes
n  at  least  two  contiguous  leads  (Q  waves  ≥  0.04  seconds
n  duration,  persistent  ST-segment  elevation  or  depres-
ion  ≥  0.1  mV).  The  time  from  symptom  onset  to  intensive
are  unit  admission  had  to  be  less  than  48  hours.
For  the  present  analysis,  we  focused  on  patients  with
T-segment  elevation  or  a  presumed  new  Q  wave  or
eft  bundle-branch  block  on  the  ﬁrst  electrocardiogram
ecorded.  The  number  of  patients  enrolled  in  the  two  orig-
nal  studies  determined  the  sample  size  and  no  formal
alculation  of  sample  size  was  performed  for  this  post  hoc
nalysis.
ata collection
sing  a  case  report  form,  attending  physicians  or  clini-
al  research  technicians  collected  detailed  information  ononditions,  treatments  prior  to  admission,  presenting  char-
cteristics,  cardiac  procedures,  medications  used  within
8  hours  of  admission  and  discharge  medications.  We  also
hospitals  (n  =  7)  Control  hospitals  (n  =  153)
112 (73.2)
32 (20.9)
7  (4.6)
2  (1.3)
27  (17.6)
26  (17.0)
26  (17.0)
49  (32.0)
26  (17.0)
26  (17.0)
42  (27.5)
81  (52.9)
30  (19.6)
94  (61.4)
90  (58.8)
39  (25.5)
 coronary intervention.
terization capabilities, two Northern Alps and 82 control hospitals
control hospitals had coronary artery bypass graft capabilities.
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documented  the  characteristics  of  the  admitting  hospital
(i.e.  location  in  the  Northern  Alps,  academic  status,  owner-
ship,  region,  number  of  licensed  beds  and  cardiac  procedure
capabilities).  Hospitals  were  identiﬁed  as  academic  hospi-
tals  based  on  whether  or  not  they  were  afﬁliated  with  a
university  [22]. Consistent  with  a  previous  study  [23], we
deﬁned  PCI  centres  as  hospitals  that  offered  emergency  PCI
24  hours/day,  7  days/week.
Regional system of care
The  RESeau  d’URgences  CORonariennes  (RESURCOR)  is  a  co-
ordinated  regional  system  of  care  for  STEMI,  which  was
implemented  in  the  Northern  Alps  in  October  2002.  It
involves  all  15  acute  care  hospitals  (including  three  PCI  cen-
tres),  three  emergency  medical  system  call  centres  and  12
mobile  emergency  care  units,  regardless  of  their  afﬁliation.
The  Northern  Alps  is  a  predominantly  mountainous  area  cov-
ering  15,000  km2,  with  an  estimated  population  of  1,860,000
inhabitants  and  large  seasonal  variations  due  to  tourism.
The  median  distance  and  driving  time  from  each  commu-
nity  hospital  to  the  closest  PCI  centre  were  63  km  (range
o
d
g
p
Figure 1. Options for initial reperfusion therapy for patients presentin
PCI: percutaneous coronary intervention.417
.5—132  km)  and  43  minutes  (range  10—88  minutes),  respec-
ively.  The  rationale  and  primary  outcomes  of  the  RESURCOR
ave  been  reported  in  detail  elsewhere  [24].
As  part  of  the  RESURCOR,  a  triage  algorithm  and  a
et  of  treatment  protocols  for  coronary  reperfusion  were
stablished  according  to  published  guidelines  and  available
esources,  and  were  approved  by  representatives  of  the
mergency  medical  system  call  centre,  mobile  emergency
are  unit,  emergency  department,  coronary  care  unit  and
nterventional  staff.  The  triage  algorithm  and  treatment
rotocols  were  disseminated  through  pocket  cards  (Fig.  1)
nd  booklets,  and  were  made  available  on  a  dedicated  web-
ite  (www.renau.org).  The  recommendations  were  reviewed
nd  eventually  updated  according  to  the  most  recent  pub-
ished  evidence  on  a  yearly  basis.
Brieﬂy,  the  triage  algorithm  recommended  that  physi-
ians  at  emergency  medical  system  call  centres  who
eceived  a  call  from  a  patient  with  symptoms  suggestive
f  acute  myocardial  infarction  lasting  less  than  12  hours
ispatch  a  mobile  emergency  care  unit  [25]. Mobile  emer-
ency  care  units  were  staffed  by  emergency  or  critical  care
hysicians  who  might  administer  prehospital  ﬁbrinolysis  or
g with ST-segment elevation myocardial infarction (STEMI) (2002).
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ctivate  the  closest  catheterization  laboratory  en  route  for
rimary  PCI,  depending  on  anticipated  delays  in  reperfusion.
mergency  department  physicians  at  hospitals  without  PCI
apability  evaluated  self-transported  STEMI  patients  with
ymptoms  lasting  less  than  12  hours  for  reperfusion  with
ither  primary  PCI  at  the  closest  PCI  centre  or  hospital
brinolysis.  Our  triage  protocol  advocated  that  patients
ndergo  rescue  PCI  after  failed  ﬁbrinolysis  and  routine  early
oronary  angiography  and  intervention  within  12  hours  of
uccessful  ﬁbrinolysis  [26]. Patients  transferred  for  primary
CI  were  transported  by  mobile  emergency  care  units  and
aken  directly  to  the  catheterization  laboratory  without  re-
valuation  in  the  emergency  department.
An  ongoing  registry  collected  prospective  detailed  data
n  time  to  treatment,  clinical  baseline  characteristics  and
oronary  angiography  ﬁndings,  to  provide  each  hospital
ith  feedback  on  aggregated  quality  data.  Physicians  were
nvited  to  an  annual  meeting  where  the  overall  policy  of
he  RESURCOR  and  the  trends  in  timely  reperfusion  therapy
ere  presented  and  discussed  [27].
utcome measures
he  primary  effectiveness  outcome  was  the  receipt  of  any
eperfusion  therapy,  either  with  primary  PCI  or  ﬁbrinolysis.
he  secondary  effectiveness  outcomes  included  the  receipt
f  prehospital  ﬁbrinolysis,  any  (i.e.  either  prehospital  or  hos-
ital)  ﬁbrinolysis,  primary  PCI  and  rescue  or  routine  early
oronary  angiography  or  intervention  after  ﬁbrinolysis.
The  clinical  outcome  was  1-year  all-cause  mortality.
eath  was  determined  from  medical  records  and  follow-up
elephone  interviews  with  the  patients’  relatives  or  their
rimary  care  physician  1  year  after  the  index  admission.  The
iving  status  of  patients  lost  to  follow-up  was  ascertained
sing  their  birthplace  census  record.
tatistical analysis
ategorical  variables  were  expressed  as  frequency  and  per-
entage  and  continuous  variables  as  median  and  25th  and
5th  percentiles  (interquartile  range  [IQR]).  Differences  in
aseline  characteristics  and  acute  medications  between
re-  and  postintervention  periods  within  each  study  group
ere  compared  using  the  Wilcoxon  rank  sum  test  for  contin-
ous  variables  and  the  chi-square  test  or  Fisher’s  exact  test
hen  appropriate  for  categorical  variables.
To  account  for  the  study  design,  we  compared  the
rimary  and  secondary  effectiveness  outcomes  using  a  logis-
ic  regression  model  that  contained  the  study  group  (i.e.
orthern  Alps  versus  control  hospitals),  study  period  (pre-
ersus  postintervention  period)  and  a  ﬁrst-order  interaction
etween  study  group  and  period.  We  computed  absolute
hange  between  2000  and  2005  within  each  study  group,
hen  we  derived  differences  in  change  between  study  groups
rom  the  logistic  regression  models  [28]. We  computed  P
alues  and  95%  conﬁdence  intervals  based  on  the  standard
rrors  estimated  by  the  delta  method.
We  used  Kaplan—Meier  estimates  and  the  stratiﬁed  log-
ank  test  to  compare  the  cumulative  1-year  mortality
cross  study  groups  between  2000  and  2005.  In  multivari-
ble  analysis,  we  estimated  hazard  ratios  for  death  using
 Cox  proportional  hazard  model  after  adjusting  for  age,
2
r
P
gJ.  Labarère  et  al.
ender,  systolic  blood  pressure  and  previous  myocardial
nfarction.
Two-sided  P  values  less  than  0.05  were  considered  sta-
istically  signiﬁcant.  All  analyses  were  performed  using
tata  version  11.0  (Stata  Corporation,  College  Station,  TX,
SA).
esults
he  analytical  sample  comprised  2479  STEMI  patients,
ncluding  102  patients  admitted  to  seven  Northern  Alps  hos-
itals  and  2377  patients  admitted  to  153  control  hospitals.
ore  patients  were  enrolled  in  2005  than  in  2000  in  both
tudy  groups  (34  and  1076  in  2000  vs  68  and  1301  in  2005,
espectively).
The  median  age  for  all  patients  was  66  years  (IQR,
3—77  years),  1762  (71%)  were  men,  512  (21%)  presented
ith  a  Killip  class  II  or  higher  and  1373  (55%)  were  admit-
ed  by  a  mobile  emergency  care  unit.  In  2005,  a  higher
ercentage  of  patients  were  admitted  to  PCI  centres  and
ad  a  medical  history  of  hypertension  in  both  study  groups
Table  2).  Enrolment  in  2005  was  also  associated  with  higher
lood  pressure  on  admission,  higher  prevalence  of  family
istory  of  coronary  artery  disease  and  more  frequent  use
f  statins  for  control  hospitals  only,  although  our  study  was
ikely  to  be  underpowered  to  detect  differences  of  similar
agnitude  for  the  Northern  Alps  study  group.  In  contrast,
atients  admitted  to  control  hospitals  in  2005  were  less
ikely  to  report  delayed  presentation  or  a  medical  history
f  previous  myocardial  infarction  or  peripheral  vascular  dis-
ase.
Overall,  patients  enrolled  in  2005  were  more  likely  to
eceive  any  reperfusion  therapy  (60%  vs  52%;  P  <  0.001),  pre-
ospital  ﬁbrinolysis  (33%  vs  15%;  P  <  0.001)  and  primary  PCI
32%  vs  26%;  P  <  0.001)  than  those  enrolled  in  2000.  The  abso-
ute  change  in  the  use  of  prehospital  ﬁbrinolysis  was  greater
or  Northern  Alps  hospitals  (Table  3),  with  a  parallel  increase
n  the  percentage  of  patients  undergoing  rescue  or  early  rou-
ine  coronary  angiography  or  intervention  after  ﬁbrinolysis
Table  3).
Between  2000  and  2005,  the  median  time  from  symp-
om  onset  to  ﬁbrinolysis  decreased  from  180  minutes  (IQR
20—240  minutes)  to  130  minutes  (IQR  90—210  minutes),
hile  the  median  time  from  symptom  onset  to  primary
CI  increased  from  240  minutes  (IQR  150—360  minutes)  to
93  minutes  (IQR  195—510  minutes)  and  the  median  time
rom  admission  to  primary  PCI  increased  from  45  minutes
IQR  20—80  minutes)  to  60  minutes  (IQR  25—144  minutes)
P  <  0.001  for  all  comparisons).  Enrolment  in  2005  was
ssociated  with  a  more  frequent  use  of  low-molecular-
eight  heparin,  platelet  glycoprotein  IIb/IIIa  receptor
gonists  and  statins  for  Northern  Alps  and  control  hospitals
Table  4).
Patients  enrolled  in  2005  experienced  lower  1-year  mor-
ality  rates  than  those  enrolled  in  2000  in  the  Northern
lps  (7.4%  vs  8.8%)  and  control  (12.6%  vs  16.8%)  hospitals
P  =  0.002)  (Fig.  2).  In  multivariable  analysis,  enrolment  in
005  remained  associated  with  a  decreased  adjusted  hazard
atio  for  death  (0.70,  95%  conﬁdence  interval  0.57—0.87;
 =  0.001),  with  no  signiﬁcant  interaction  between  study
roups  (adjusted  hazard  ratios  0.77  and  0.70  for  Northern
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Table  2 Baseline  characteristics  stratiﬁed  by  study  year  for  patients  enrolled  in  Northern  Alps  and  control  hospitals.
Characteristicsa Northern  Alps  hospitals Control  hospitals
2000  (n  =  34) 2005  (n  =  68) P 2000  (n  =  1076) 2005  (n  =  1301) P
Male  sex 27 (79.4)  51 (75.0)  0.62  776 (72.1)  908 (69.8)  0.21
Age  (years) 67 (55—78) 65 (54—77) 0.74  67 (53—76) 66 (53—77) 0.91
Admission  by  mobile  emergency  care  unit 22 (64.7)  38 (55.9)  0.39  611 (56.8)  702 (54.0)  0.17
Admission  to  hospital  with  PCI  capability 19 (55.9)  58 (85.3)  0.001  768 (71.4)  1040 (79.9)  <  0.001
Presentation  within  3  hours  of  symptom  onset 11 (32.3)  25 (36.8)  0.66  284 (27.6)  571 (43.9)  <  0.001
Presenting  characteristics
Heart  rate  (beats/minute) 80 (67—88) 74 (60—90) 0.79  75 (65—90) 77 (65—90) 0.30
Systolic  blood  pressure  (mmHg) 122 (110—140) 130 (115—148) 0.38  130 (114—150) 133 (116—150) 0.006
Killip  class 0.14 0.20
I 29 (85.3)  57 (83.8)  850 (79.1)  1028 (79.1)
II 1 (2.9)  8 (11.8)  143 (13.3)  155 (11.9)
III 2 (5.9)  3 (4.4)  52 (4.8)  86 (6.6)
IV 2 (5.9)  0 (0)  30 (2.8)  30 (2.3)
LVEF  ≤  35% 2 (6.5)  7 (11.7)  0.71  136 (14.0)  146 (14.0)  0.98
Anterior  ST-segment  elevation 11 (32.4)  22 (32.4)  0.99  413 (38.4)  496 (38.1)  0.90
Medical  history
Diabetes  mellitus 6  (17.7)  9  (13.2)  0.56  227  (21.1)  264  (20.3)  0.63
Hypertension 9  (26.5)  33  (48.5)  0.03  485  (45.1)  661  (50.8)  0.005
Hypercholesterolaemia 10 (29.4)  25 (36.8)  0.46  437 (40.6)  564  (43.4)  0.18
Current  smoking 11 (32.4)  24 (35.3)  0.77  383 (35.6)  463 (35.6)  0.99
Family  history  of  CAD 7 (20.6)  20 (29.4)  0.34  174 (16.2)  314  (24.1)  <  0.001
Peripheral  arterial  disease 3 (8.8)  4 (6.1)  0.69  98  (9.1)  88  (6.8)  0.04
Previous  stroke 1 (2.9)  0 (0)  0.34  45 (4.2)  62  (4.8)  0.49
Previous  myocardial  infarction 3 (8.8)  8 (11.8)  0.75  176  (16.4)  164  (12.6)  0.009
Previous  PCI 1 (2.9)  4 (5.9)  0.66  89  (8.3)  123  (9.5)  0.31
Previous  CABG 1 (2.9)  1 (1.5)  0.99  35  (3.3)  38  (2.9)  0.64
Previous  congestive  heart  failure 2 (5.9)  1 (1.5)  0.27  53  (4.9)  58  (4.5)  0.60
Chronic  renal  disease 2 (5.9)  2 (3.0)  0.60  43  (4.0)  54  (4.2)  0.84
Previous  use  of  medical  therapy
Antiplatelet  agents 3 (8.8)  11  (16.2)  0.38  252  (23.4)  298  (22.9)  0.77
Beta-blockers 2  (5.9)  9  (13.2)  0.33  201  (18.7)  242  (18.6)  0.96
Statins 3 (8.8)  12  (17.6)  0.37  189  (17.6)  293  (22.5)  0.003
ACE  inhibitors 5  (14.7)  9  (13.2)  0.84  153  (14.2)  192  (14.8)  0.71
Data are number (%) or median (25th—75th percentiles). ACE: angiotensin-converting enzyme; CABG: coronary artery bypass graft; CAD: coronary artery disease; LVEF: left ventricular
ejection fraction; PCI: percutaneous coronary intervention.
a Values were missing for age (n = 1), time to presentation (n = 51), heart rate (n = 17), systolic blood pressure (n = 19), Killip class (n = 3), left ventricular ejection fraction (n = 374),
peripheral arterial disease (n = 5), previous stroke (n = 4), previous congestive heart failure (n = 4) and chronic renal disease (n = 5).
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Table  3 Reperfusion  therapy  stratiﬁed  by  study  year  for  patients  enrolled  in  Northern  Alps  and  control  hospitals.
Revascularization  strategy Northern  Alps  hospitals  Control  hospitals  Percentage  point
difference  in  change
(95%  CI)
P
2000 2005 Absolute  change  (%) 2000 2005 Absolute
change  (%)
Any  reperfusion  17/34  (50.0)  42/68  (61.8)  11.8  557/1076  (51.8)  778/1301  (59.8)  8.0* 3.8  (−17.1  to  24.5)  0.72
Fibrinolysis  11/34  (32.3)  33/68  (48.5)  16.2  278/1076  (25.8)  345/1301  (26.5)  0.7  15.5  (−4.5  to  35.5)  0.13
Prehospital  ﬁbrinolysisa 4/22  (18.2)  24/38  (63.2)  45.0* 89/611  (14.6)  222/702  (31.6)  17.0* 28.0  (5.2  to  50.6)  0.02
Primary  PCI  6/34  (17.6)  9/68  (13.2)  −4.4  279/1076  (25.9)  433/1301  (33.3)  7.3* −11.7  (−27.3  to  3.8)  0.14
Rescue  or  routine  PCI  3/34  (8.8)  30/68  (44.1)  35.3* 74/1076  (6.9)  288/1301  (22.1)  15.2* 20.1  (4.6  to  35.4)  0.01
Data are n/n (%) unless otherwise indicated. CI: conﬁdence interval; PCI: percutaneous coronary intervention.
a The percentage of patients receiving prehospital ﬁbrinolysis was computed among patients admitted by mobile emergency care units.
* P < 0.01.
Table  4  Acute  medications  and  length  of  stay  stratiﬁed  by  study  year  for  patients  enrolled  in  Northern  Alps  and  control  hospitals.
Northern  Alps  hospitals  Control  hospitals
2000  (n  =  34)  2005  (n  =  68)  P  2000  (n  =  1076)  2005  (n  =  1301)  P
Acute  medications
Unfractionated  heparin  31  (91.2)  41  (60.3)  0.001  854  (79.4)  861  (66.2)  <  0.001
Low-molecular-weight  heparin  1  (2.9)  53  (77.9)  <  0.001  313  (29.1)  800  (61.5)  <  0.001
Platelet  glycoprotein  IIb/IIIa  receptor  agonists  4  (11.8)  24  (35.3)  0.02  235  (21.8)  458  (35.2)  <  0.001
Antiplatelet  agents  31  (91.2)  65  (95.6)  0.40  1033  (96.0)  1247  (95.8)  0.85
Beta-blockers  19  (55.9)  53  (77.9)  0.02  779  (72.4)  922  (70.9)  0.41
Statins  11  (32.4)  51  (75.0)  <  0.001  522  (48.5)  1015  (78.0)  <  0.001
ACE  inhibitors  8  (23.5)  22  (32.4)  0.36  431  (40.1)  652  (50.1)  <  0.001
Length  of  stay  (days)  10  (7—14)  7  (5—13)  0.41  10  (8—14)  8  (6—12)  <  0.001
Data are number (%) or median (25th—75th percentiles). ACE: angiotensin-converting enzyme.
The length of stay was censored at the time of death for patients who died in the hospital.
Regional  system  of  care  for  myocardial  infarction  
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critical  care  physicians  [25]. This  allows  early  recognitionFigure 2. Comparison of cumulative mortality stratiﬁed by study
group (P = 0.002).
Alps  and  control  hospitals,  respectively;  P  for  interac-
tion  =  0.92).
Discussion
Consistent  with  previous  reports,  this  pooled  analysis  of
two  nationwide  prospective  cohort  studies  shows  substan-
tial  progress  in  reperfusion  rates  for  STEMI  patients  between
2000  and  2005  in  France.  This  study  also  indicates  that  the
implementation  of  a  regional  system  of  care  was  followed
by  more  frequent  use  of  prehospital  ﬁbrinolysis  and  rescue
or  routine  early  coronary  angiography  or  intervention  after
ﬁbrinolysis,  relative  to  control  hospitals.
The  management  of  acute  myocardial  infarction  and
emergency  medical  systems  evolved  between  2000  and
2005,  and  the  increasing  use  of  prehospital  thrombolysis
might  have  been  observed  without  any  regional  initiative
in  the  Northern  Alps.  However,  our  ﬁndings  were  adjusted
for  secular  trends  and  sudden  changes,  using  a  controlled
pre-  and  postintervention  study  design.
Despite  similar  admission  rates  by  mobile  emergency  care
units,  the  largest  difference  in  change  between  the  two
study  groups  involved  prehospital  ﬁbrinolysis  (28  percentage
points).  This  observation  likely  reﬂects  compliance  with  our
regional  policy  that  advocates  rapid  administration  of  ﬁb-
rinolysis  for  patients  with  prohibitive  anticipated  delays  in
primary  PCI.  The  more  frequent  use  of  ﬁbrinolysis  in  the  pre-
hospital  setting  also  partly  explains  the  concomitant  decline
in  time  from  symptom  onset  to  ﬁbrinolysis.
Importantly,  a  difference  in  change  of  similar  magni-
tude  to  that  observed  for  the  use  of  prehospital  ﬁbrinolysis
was  found  in  the  percentages  of  patients  undergoing  res-
cue  or  routine  early  coronary  angiography  or  intervention
after  ﬁbrinolysis  (20  percentage  points).  This  result  may  be
attributed  to  the  opening  of  a  new  PCI  centre  without  onsite
coronary  artery  bypass  graft  capability  in  2002  in  the  North-
ern  Alps.  It  also  reﬂects  a  referral  practice  supported  by  the
ﬁndings  from  the  CAPTIM  trial,  which  failed  to  evidence  any
long-term  survival  advantage  for  primary  PCI  relative  to  a
strategy  of  prehospital  ﬁbrinolysis  followed  by  admission  to
o
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 PCI  hospital  [29]. Overall,  the  FAST-MI  study  showed  that
atients  receiving  a  pharmacoinvasive  strategy  that  com-
ined  ﬁbrinolysis  with  a  liberal  use  of  PCI  had  a  similar  1-year
ortality  rate  to  patients  undergoing  primary  PCI  [21]. This
nding  has  been  conﬁrmed  by  randomized  trials  that  demon-
trated  the  beneﬁt  of  routine  early  transfer  for  PCI  after
brinolysis  [30].
In contrast,  the  use  of  primary  PCI  improved  in  control
ospitals  only,  although  no  signiﬁcant  difference  in  change
as  found  between  the  two  study  groups.  Meanwhile,  the
ime  to  primary  PCI  dramatically  increased,  reﬂecting  the
ifﬁculties  achieving  timely  primary  PCI,  especially  for
atients  ﬁrst  admitted  to  hospitals  without  PCI  capability.
his  observation  is  consistent  with  the  so-called  reperfu-
ion  paradox,  in  which  efforts  to  increase  access  to  primary
CI  for  all  STEMI  patients  leads  to  unnecessary  avoidance  of
imely  ﬁbrinolysis  and  delays  in  reperfusion  therapy  [31].
Despite  a  substantial  difference  in  1-year  mortality  at
aseline  (8.8%  vs  16.8%),  the  two  study  groups  yielded  a
omparable  decline  in  adjusted  hazard  ratios  for  death
0.77  and  0.70)  in  2005.  Although  we  cannot  exclude  that
ur  analysis  was  underpowered  to  detect  small  but  clin-
cally  signiﬁcant  differences  in  mortality,  this  ﬁnding  may
e  explained  by  the  similar  increases  in  the  percentage  of
atients  receiving  reperfusion  therapy,  either  mechanical
r  pharmacological,  across  the  two  study  groups  (11.8  and
.0  percentage  points).  As  noted  by  others  [1],  the  timely
se  of  some  reperfusion  therapy  may  be  more  important
han  the  reperfusion  therapy  option.  Consistently,  a  recent
tudy  reported  substantial  reductions  in  mortality  rates  fol-
owing  the  initiation  of  the  Reperfusion  of  Acute  Myocardial
nfarction  in  North  Carolina  Emergency  Departments  (RACE)
rogramme,  but  these  changes  mirrored  those  observed  in
tatewide  control  hospitals  and  those  observed  nationally
32].
Although  we  cannot  determine  which  component  of
ur  regional  system  of  care  for  STEMI  patients  was  most
ffective  in  improving  processes  of  care,  several  aspects  dis-
inguish  our  initiative  from  previous  research  [13,15,17,18].
irst,  our  system  of  care  has  been  implemented  through
n  integrated  network  encompassing  all  hospital-based
tructures  in  charge  of  patients  with  STEMI  (i.e.  emer-
ency  medical  service  call  centres,  mobile  emergency  care
nits,  emergency  departments,  intensive  care  units  and
atheterization  laboratories),  regardless  of  their  afﬁlia-
ion.  Interhospital  transfer  protocols  have  been  approved
y  representatives  of  each  participating  hospital;  this  is
n  accordance  with  a  previous  modelling  study  showing
hat  a  strategy  of  transporting  every  patient  to  an  exist-
ng  PCI  centre  is  less  costly  and  more  effective  than  various
ospital  expansion  options  [33]. To  avoid  the  diversion  of
atients  from  local  community  hospitals  without  PCI  capa-
ility,  patients  directed  to  PCI  centres  are  transferred  to
heir  local  hospitals  soon  after  their  procedure.
Second,  unlike  other  systems  for  reperfusion  that  rely
n  local  ambulances  [1],  both  prehospital  transportation
nd  interhospital  transfer  of  STEMI  patients  are  operated
y  mobile  emergency  care  units  staffed  by  emergency  orf  STEMI,  substantial  reduction  in  delays  in  reperfusion
herapy  and  management  of  life-threatening  complications,
uch  as  arrhythmias,  during  transportation  [34]. Despite  long
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istances  or  driving  times,  our  system  of  care  relied  predom-
nantly  on  ground  medical  transport,  although  other  systems
dvocate  helicopter  transfer  when  the  anticipated  trans-
ort  time  is  longer  than  40  minutes  [13]. However,  some
eneral  practitioners  in  ski  resorts  or  sparsely  populated
reas  may  administer  prehospital  ﬁbrinolysis  to  provide
imely  access  to  reperfusion  therapy,  as  part  of  our  regional
nitiative  [35].
Third,  the  regional  healthcare  authority  played  a  leading
ole  in  encouraging  the  development  of  our  integrated  net-
ork.  Financial  incentives  and  contract  arrangements  were
et  up  to  encourage  collaboration  between  PCI  and  non-PCI
ospitals.  A  dedicated  team  is  funded  to  ensure  the  coordi-
ation  and  maintenance  of  the  regional  system  of  care.  The
mpact  of  regionalization  on  access  to  timely  reperfusion  is
onitored  continuously.
tudy limitations
ome  study  limitations  deserve  mention.  First,  this  study
as  not  randomized  in  design  and  therefore  the  results  may
e  confounded  by  differences  in  casemix  as  well  as  secu-
ar  trend  or  sudden  changes  in  processes  of  care.  Yet,  unlike
revious  reports,  our  study  included  a  control  group  consist-
ng  of  153  hospitals  in  order  to  account  for  evolving  therapies
nd  other  temporal  factors.  Moreover,  this  observational
tudy  addresses  an  important  question  that  is  unlikely  to  be
tudied  by  randomized  controlled  trials  because  the  imple-
entation  of  systems  of  care  for  STEMI  depends  on  many
actors,  including  legislation  and  local  policies,  available
esources,  purchaser  and  payer  interests  and  population
references.
Second,  the  limited  sample  size  implied  that  estimates
ere  imprecise  and  potentially  unreliable  for  processes  of
are  and  outcomes  among  patients  enrolled  in  Northern  Alps
ospitals.  Although  the  ﬁndings  support  our  study  hypothe-
is,  they  should  be  regarded  with  caution.
Third,  to  the  best  of  our  knowledge,  no  concurrent  initia-
ive  involving  control  hospitals  was  implemented  between
000  and  2005,  although  this  possibility  cannot  be  formally
uled  out.  However,  such  concurrent  initiatives  would  con-
ribute  to  attenuating  the  differences  in  processes  of  care
nd  patient  outcomes  observed  between  Northern  Alps  and
ontrol  hospitals.
Fourth,  seven  of  15  (47%)  Northern  Alps  hospitals  and
53  of  359  (43%)  control  hospitals  participated,  on  a  vol-
ntary  basis,  in  the  USIC  2000  and  FAST-MI  studies.  Hence,
hey  may  not  be  representative  of  the  hospitals  with  inten-
ive  care  units  that  treated  patients  with  acute  myocardial
nfarction  in  France.  Additionally,  these  ﬁndings  may  not
xtend  to  patients  treated  in  other  geographical  locations
ecause  processes  of  care  for  patients  with  acute  myocardial
nfarction  have  been  shown  to  vary  across  countries.
Fifth,  our  study  was  based  on  data  collected  in  2000  and
005  and  may  not  reﬂect  current  practices.  Our  regional
olicy  has  evolved,  promoting  a  more  frequent  use  of  pri-
ary  PCI  for  patients,  with  timely  access  to  PCI  centres
n  order  to  comply  with  published  evidence.  Unfortunately,
ore  recent  data  were  not  available  to  address  this  issue  at
he  time  the  present  analysis  was  performed.J.  Labarère  et  al.
onclusion
n  conclusion,  regionalization  of  care  in  a predominantly
ountainous  area  improved  access  to  timely  reperfusion
herapy  through  the  more  frequent  use  of  prehospital  ﬁb-
inolysis  and  rescue  or  routine  early  PCI  after  ﬁbrinolysis.
hese  ﬁndings  provide  additional  support  for  implementing
egional  systems  of  care  for  STEMI,  although  their  impact  on
linical  outcomes  deserves  further  study.
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